4 Nov 2021 | Press release
TechnoPhage is proud to announce that the first part of the Phase I/IIa Clinical Trial with TP-102 (REVERSE study) has been completed. The study aims to assess the safety and tolerability of this product in individuals with diabetic foot ulcers. According to the data...
15 Out 2021 | Press release
We are proud to announce that a potential new therapeutic antibody for the treatment of COVID-19 has been identified. The candidate antibody was born from a research project started in 2020, having obtained promising neutralization results, even against the most...
14 Mai 2021 | Press release
Technophage announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TP-102, the company’s first bacteriophage cocktail, for the treatment of infected diabetic foot ulcers caused by three different bacteria (Pseudomonas...
5 Mai 2021 | Press release
In a joint effort to tackle Alzheimer’s Disease (AD), Technophage in collaboration with ICNAS (Instituto de Ciências Nucleares Aplicadas à Saúde) is developing a diagnostic solution in PET imaging for this overwhelming pathology. The experience of the company...
24 Fev 2021 | Press release
TechnoPhage announced the beginning of Phase I/IIa study (REVERSE) of TP-102, a phage therapy candidate for the treatment of Diabetic Foot Infections (DFI). The first-in-human study is designed to evaluate the safety and tolerability of TP-102 in subjects with both...
6 Out 2020 | Press release
U.S. FDA has just cleared the IND application of bacteriophage cocktail TP-102 to initiate Phase I/IIa clinical trial. TP-102 is a cocktail of five bacteriophages that is being developed for the topical treatment of diabetic foot ulcers against Staphylococcus aureus,...
